Physician profile
Marina Collins
NPI 1164176194
$3,410.62
in general payments reported to CMS, 2019-2025
30 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $438 · 2023: $941 · 2024: $997 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $558.05 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $343.41 | 2023-2025 | Dovato, Cabenuva, Rukobia |
| Sanofi-Aventis U.S. LLC | $284.65 | 2024-2025 | |
| Novo Nordisk INC | $265.42 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $224.22 | 2022-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.47 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $215.06 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $214.58 | 2023-2025 | |
| Pfizer INC. | $126.21 | 2023-2025 | |
| Genzyme Corporation | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $103.46 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.24 | 2023 | |
| Phathom Pharmaceuticals, INC. | $91.89 | 2024-2025 | Voquezna |
| Amgen INC. | $74.67 | 2023-2024 | Repatha, Otezla, Krystexxa |
| Medtronic, INC. | $69.84 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.33 | 2023-2024 | |
| Corcept Therapeutics | $48.86 | 2024 | Korlym |
| Sumitomo Pharma America, INC. | $44.07 | 2024-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $38.88 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $38.54 | 2025 | Pifeltro, Capvaxive, Delstrigo |
| Janssen Pharmaceuticals, INC | $22.62 | 2023 | Spravato |
| Dexcom, INC. | $21.48 | 2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $20.62 | 2024 | Bd Max System, Bd Max Instrument |
| Electromed, INC. | $19.31 | 2024 | Smartvest |
| Biogen, INC. | $16.28 | 2025 | Skyclarys |
| Gilead Sciences, INC. | $15.69 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $15.40 | 2024 | Rexulti |
| Pharming Healthcare, INC. | $14.47 | 2024 | Ruconest |
| Idorsia Pharmaceuticals US INC | $13.98 | 2023 | Quviviq |
| Insightec,INC | $13.92 | 2023 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.